Stockreport

aTyr Pharma Announces First Quarter 2024 Results and Provides Corporate Update

aTyr Pharma, Inc.  (LIFE) 
Last atyr pharma, inc. earnings: 3/26 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: atyrpharma.com/investors-media
PDF Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected to complete enrollment in the second quarter of 2024. Ended the first quarter 2024 with $87.7 m [Read more]